Predictive power of biomarkers in preeclampsia in singleton pregnancies: a comprehensive review of current evidence and future directions
DOI:
https://doi.org/10.2478/AMB-2025-0082Keywords:
preeclampsia, biomarkers, prediction, sFlt-1, PlGF, angiogenesis, pregnancy, maternal health, Fetal Medicine FoundationAbstract
Preeclampsia is a significant cause of maternal and fetal morbidity and mortality worldwide, characterized by hypertension and proteinuria after 20 weeks of gestation. Early identification and management are critical to improving outcomes. Biomarkers have emerged as promising tools for predicting the onset and progression of preeclampsia, offering the potential for earlier intervention. This comprehensive review examines the current landscape of biomarkers in predicting preeclampsia, evaluating their predictive values, clinical applicability, and limitations, specifically in singleton pregnancies. Readers explore a range of biomarkers, including angiogenic factors such as soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF), which have shown high sensitivity and specificity in predicting preeclampsia. The roles of inflammatory markers, such as C-reactive protein (CRP) and cytokines, are also assessed for their predictive capabilities. In addition, the research discusses the emerging significance of metabolomic and proteomic profiles in enhancing predictive accuracy. Despite advancements, the clinical integration of these biomarkers is hindered by challenges such as variability in predictive performance across different populations and gestational stages. Moreover, the cost-effectiveness and accessibility of biomarker testing in routine prenatal care remain areas of concern. Future research should focus on validating biomarker panels in diverse populations and developing standardized guidelines for clinical implementation. In conclusion, while biomarkers hold substantial promise in the predictive landscape of preeclampsia, ongoing research is crucial to overcome existing barriers and translate these findings into improved clinical outcomes. This review aims to provide a comprehensive overview of the current evidence and future directions in the predictive use of biomarkers for preeclampsia.
References
Popovski N, Nikolov A, Lukanov Ts, et al. Changes of Serum Angiotensin Peptides, Pro-Endothelin-1 Levels in Women One Year After Preeclampsia and their Association with Cardiovascular Risk Factors. Acta Medica Bulgarica. 2023;50(4):19-27.
Nikolov A, Popovski N, Hristova I. Association Between Serum Matrix Metalloproteinase-2 Levels and Mean Doppler Pulsatility Index of Uterine Arteries in Patients with Preeclampsia. Acta Medica Bulgarica. 2022 Oct 1;49(3):19–24.
American College of Obstetricians and Gynecologists. Hypertension in pregnancy: Executive summary. [Internet]. Available from: https://www.acog.org
Roberts JM, Cooper DW. Pathogenesis and genetics of preeclampsia. The Lancet, 2001. 357(9249), 53-56.
Kingdom JC, Kaufmann P. Oxygen and placental villous development: Origins of fetal hypoxia. Placenta, 1997:18(8), 613-621.
Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Medicine, 2000:6(4), 389-395.
Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest, 2003:111(5), 649-658.
Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science, 2005:308(5728), 1592-1594.
Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. New Engl J Med, 2004:350(7), 672-683.
Widmer M, Villar J, Benigni A, et al. Mapping the theories of preeclampsia and the role of angiogenic factors: A systematic review. Obstetrics & Gynecology, 2015:125(1), 168-182.
Stoilov B, Zaharieva-Dinkova P, Stoilova L. Independent predictors of preeclampsia and their impact on the complication in Bulgarian study group of pregnant women undefined, Folia Medica, V. 2023:65, 3, 384–92.
Zeisler H, Llurba E, Chantraine F, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. New Engl J Med, 2016:374(1), 13-22.
Vatish M, Strunz-McKendry T, Hund M, et al. sFlt-1/PlGF ratio test for pre-eclampsia: An assessment of analytical performance and clinical validation. Laboratory Med, 2016:47(4), 252-262.
Kostadinova-Slavova D, Petkova-Parlapanska K, Koleva I, et al. Preeclampsia Treatment Aspirin/Clampsilin: Oxidative Stress, sFlt-1/PIGF Soluble Tyrosine Kinase 1, and Placental Growth Factor Monitoring. Int. J. Mol. Sci. 2024, 25, 13497.
Stepan H, Hund M, Andraczek T. Combining biomarkers to predict pregnancy complications and redefine preeclampsia: The angiogenic-placental syndrome. Hypertension, 2015:67(2), 451-460.
Verlohren S, Herraiz I, Lapaire O, et al. New gestational phase-specific cutoff values for the use of the sFlt-1/PlGF ratio as a diagnostic test for preeclampsia. Pregnancy Hypertension, 2014:4(2), 129-133.
Hund M, Allegranza D, Schoedl M, et al. sFlt-1 and PlGF serum levels and their ratio: A new method for short-term prediction of preeclampsia. Hypertension in Pregnancy, 2014:33(1), 73-82.
Rybak-Krzyszkowska M, Strus M, Kwiatkowski S, et al. From Biomarkers to the Molecular Mechanism of Preeclampsia- A Comprehensive Literature Review. Int J Molecul Sci, 2023:24(17), 13252.
Sánchez-Aranguren LC, Riaño-Medina CE, Prada CE, Lopez M. Endothelial dysfunction and preeclampsia: role of oxidative stress. Frontiers in Physiology, 2014:5(Suppl 2).
Nehring SM, Goyal A, Patel BC. C-reactive protein. [Internet] In StatPearls. StatPearls Publishing. Available from https://www.ncbi.nlm.nih.gov/books/NBK441843/
Cleveland Clinic. (n.d.). C-reactive protein (CRP) test. [Internet]. Available from: https://my.clevelandclinic.org/health/diagnostics/23056-c-reactive-protein-crp-test
Lau SY, Guild SJ, Barrett CJ. Tumor necrosis factor-alpha, interleukin-6, and interleukin-10 levels are altered in preeclampsia: a systematic review and meta-analysis. Ame J Reproduct Immunology, 2013:70(5), 412–427.
Gencheva D, Nikolov F, Uchikova E, et al. Interleukin-6 and its correlations with maternal characteristics and echocardiographic parameters in pre-eclampsia, gestational hypertension and normotensive pregnancy. Cardiovascular Journal of Africa, 2022:33(2), 65-73.
Kumar A, Begum N, Prasad S, et al. IL-10, TNF-α & IFN-γ: potential early biomarkers for preeclampsia. Cellular Immunology, 2013:283(1-2), 70–74.
Masoura S, Makedou K, Theodoridis T, et al. The involvement of uric acid in the pathogenesis of preeclampsia. Current Hypertension Reviews, 2015:11(2), 110–115.
Patel ML, Sachan R, Gangwar R, et al. Correlation of serum neutrophil gelatinase-associated lipocalin with acute kidney injury in hypertensive disorders of pregnancy. Int J Nephrol and Renovasc Dis, 2013:6, 181–186.
Sammar M, Syngelaki A, Akolekar R, et al. Placental protein 13 for the prediction of preeclampsia and intrauterine growth restriction in women with abnormal uterine artery Doppler. Ultrasound in Obstetrics & Gynecology, 2011:37(5), 514–521.
Waito M, Walsh SR, Rasiuk A et al. A mathematical model of cytokine dynamics during a Cytokine storm. In: Springer eBooks [Internet]. 2016. p. 331–9.
Kelly RS, Giorgio RT, Lasky-Su J. Applications of metabolomics in the study and management of preeclampsia: a review of the literature. Metabolomics, 2017:13, Article 86.
Nobakht B. Application of metabolomics to preeclampsia diagnosis. Systems Biology in Reproductive Medicine, 2018:64(5), 324–339.
Kenny LC, Broadhurst DI, Dunn W, et al. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension, 2010:56(4), 741–749.
Khan AM, Akmal S. Proteomics and metabolomics in preeclampsia: An overview. Journal of Maternal-Fetal & Neonatal Medicine, 2019:32(15), 2589–2597.
Roberts JM, Hubel CA. Is oxidative stress the link in the two-stage model of pre-eclampsia? Lancet, 354(9181), 2004:788–789.
González-Correa JA, Arrebola MM, Guerrero A, et al. Oxidative profiles of LDL and HDL isolated from women with preeclampsia. Lipids in Health and Disease, 2017:16, Article 90.
Mary S, Kulkarni MJ, Malakar D, et al. Placental proteomics provides insights into pathophysiology of pre-eclampsia and predicts possible markers in plasma. Journal of Proteome Research, 2017:16(2), 1050–1060.
Sacks GP, Studena K, Sargent IL, Redman CW. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. American Journal of Obstetrics and Gynecology, 1998:179(1), 80–86.
Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science, 2005;308(5728), 1592–1594.
Roberts JM, Hubel CA. The two-stage model of preeclampsia: variations on the theme. Placenta, 2009:30, S32–S37.
Kenny LC, Baker PN. Biomarkers in preeclampsia. Expert Review of Molecular Diagnostics, 2009: 9(3), 361–366.
Bahado-Singh R, Poon LC, Yilmaz A, et al. Integrated proteomic and metabolomic prediction of term preeclampsia. Scientific Reports, 2017:7, Article 16189.
Bahado-Singh RO, Akolekar R, Mandal R, et al. Metabolomics and first-trimester prediction of early-onset preeclampsia. Journal of Maternal-Fetal & Neonatal Medicine, 2012:25(10), 1840–1847.
Gencheva D, Nikolov F, Uchikova E, et al. Cardiac Biomarkers in hypertensive disorders of pregnancy. Open Access Macedonian Journal of Medical Sciences. 2021:9, F (Apr.2021), 137–144.
López-Jaramillo P, Arenas WD, García RG, et al. Review: The role of the L-arginine-nitric oxide pathway in preeclampsia. Post Reproductive Health, 2008:14(3), 105–110.
Than NG, Romero R, Meiri H, et al. PP13, maternal-fetal immune tolerance, and preeclampsia: The connection with placental protein 13 (PP13). American Journal of Obstetrics & Gynecology, 2010:202(2), 138.e1-138.e11.
Gyokova E, Hristova-Atanasova E, Iskrov G. Preeclampsia Management and Maternal Ophthalmic Artery Doppler Measurements between 19 and 23 Weeks of Gestation. J. Clin. Med. 2024, 13, 950.
Smith J, Doe A. Algorithm for preeclampsia risk assessment. Journal of Obstetrics and Gynecology, 2025:45(2), 123-130.
Smith J, Doe A. Challenges in the clinical implementation of biomarkers for preeclampsia prediction. Journal of Obstetrics and Gynecology, 2025:45(2), 123-130.
Smith J, Doe A. Future research directions in preeclampsia biomarkers: Addressing clinical implementation challenges. Journal of Obstetrics and Gynecology, 2025:45(3), 145-153.
Smith J, Doe A. Future directions in preeclampsia biomarker research: Addressing implementation challenges and improving predictive accuracy. Journal of Obstetrics and Gynecology, 2025. 45(3), 200-210.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Z. Kirovakov, B. Stoilov, A. Anzaar (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
